Primatene Mist is owned by Armstrong Pharms.
Primatene Mist contains Epinephrine.
Primatene Mist has a total of 1 drug patent out of which 0 drug patents have expired.
Primatene Mist was authorised for market use on 07 November, 2018.
Primatene Mist is available in aerosol, metered;inhalation dosage forms.
The generics of Primatene Mist are possible to be released after 26 January, 2026.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US8367734||ARMSTRONG PHARMS||Stable epinephrine suspension formulation with high inhalation delivery efficiency|| |
(2 years from now)
Market Authorisation Date: 07 November, 2018
Dosage: AEROSOL, METERED;INHALATION
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic